Literature DB >> 18759007

Crosstalk of liver, bile ducts and the gut.

Ulrich Beuers1.   

Abstract

A complex interplay of liver, bile ducts, and the gut critically determines functioning of these organs in health and disease. Biochemical and physiological aspects of their interaction and the role of inflammatory cells, cytokines, bile acids, visceral hormones, neuropeptides and other messengers in the pathogenesis of model immune-mediated hepatobiliary disorders are discussed in the actual issue of Clinical Reviews in Allergy and Immunology. Potential molecular targets for future therapeutic approaches are also addressed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18759007     DOI: 10.1007/s12016-008-8084-z

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  25 in total

Review 1.  Innate and adaptive immune response to apoptotic cells.

Authors:  Yufeng Peng; David A Martin; Justin Kenkel; Kang Zhang; Carol Anne Ogden; Keith B Elkon
Journal:  J Autoimmun       Date:  2007-09-20       Impact factor: 7.094

Review 2.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 3.  The causes of primary biliary cirrhosis: Convenient and inconvenient truths.

Authors:  M Eric Gershwin; Ian R Mackay
Journal:  Hepatology       Date:  2008-02       Impact factor: 17.425

4.  Autoimmunity and pathophysiology.

Authors:  Ioannis A Tsonis; Stratis Avrameas; Haralampos M Moutsopoulos
Journal:  J Autoimmun       Date:  2007-09-19       Impact factor: 7.094

5.  Repertoire-dependent immunopathology.

Authors:  Joshua Milner; Jerrold Ward; Andrea Keane-Myers; Booki Min; William E Paul
Journal:  J Autoimmun       Date:  2007-09-21       Impact factor: 7.094

Review 6.  Control of cholangiocyte adaptive responses by visceral hormones and neuropeptides.

Authors:  Marco Marzioni; Giammarco Fava; Domenico Alvaro; Gianfranco Alpini; Antonio Benedetti
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

7.  High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.

Authors:  Susan N Cullen; Christian Rust; Kenneth Fleming; Cathryn Edwards; Ulrich Beuers; Roger W Chapman
Journal:  J Hepatol       Date:  2008-02-14       Impact factor: 25.083

Review 8.  Medical treatment of cholestatic liver disease.

Authors:  Gustav Paumgartner; Thomas Pusl
Journal:  Clin Liver Dis       Date:  2008-02       Impact factor: 6.126

Review 9.  Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease.

Authors:  David H Adams; Bertus Eksteen
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

Review 10.  Inflammatory pathways in liver homeostasis and liver injury.

Authors:  Frank Tacke; Tom Luedde; Christian Trautwein
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 10.817

View more
  4 in total

Review 1.  The immunopathology of human biliary cell epithelium.

Authors:  Ya-Hui Chuang; Ruth Y Lan; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

Review 2.  Advances in cholangiocyte immunobiology.

Authors:  Gaurav Syal; Michel Fausther; Jonathan A Dranoff
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-09-06       Impact factor: 4.052

3.  Substance P increases liver fibrosis by differential changes in senescence of cholangiocytes and hepatic stellate cells.

Authors:  Ying Wan; Fanyin Meng; Nan Wu; Tianhao Zhou; Julie Venter; Heather Francis; Lindsey Kennedy; Trenton Glaser; Francesca Bernuzzi; Pietro Invernizzi; Shannon Glaser; Qiaobing Huang; Gianfranco Alpini
Journal:  Hepatology       Date:  2017-06-19       Impact factor: 17.425

Review 4.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.